Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138


[Impact of an automated dispensing system for medical devices in cardiac surgery department].

Clou E, Dompnier M, Kably B, Leplay C, Poupon E, Archer V, Paul M.

Ann Pharm Fr. 2018 Jan;76(1):64-70. doi: 10.1016/j.pharma.2017.10.003. Epub 2017 Nov 23. French.


Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer.

Henschke CI, Yankelevitz DF, Yip R, Archer V, Zahlmann G, Krishnan K, Helba B, Avila R.

J Med Imaging (Bellingham). 2016 Jul;3(3):035505. doi: 10.1117/1.JMI.3.3.035505. Epub 2016 Sep 20.


Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T.

Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2.


A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M.

J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.


Heroin use impairs smoking cessation among Australian prisoners.

Indig D, Wodak AD, Richmond RL, Butler TG, Archer VA, Wilhelm KA.

BMC Public Health. 2013 Dec 19;13:1200. doi: 10.1186/1471-2458-13-1200.


[Evaluation of ownership of an implantable medical device by patients].

Salles M, Amet D, Archer V, Elbaz N, Teiger E, Paul M, Astier A.

Ann Pharm Fr. 2013 Nov;71(6):423-8. doi: 10.1016/j.pharma.2013.06.004. Epub 2013 Oct 14. French.


Adult ADHD Among NSW Prisoners: Prevalence and Psychiatric Comorbidity.

Moore E, Sunjic S, Kaye S, Archer V, Indig D.

J Atten Disord. 2016 Nov;20(11):958-967. Epub 2013 Oct 17.


Safety of a novel high tibial osteotomy locked plate fixation for immediate full weight-bearing: a case-control study.

Hernigou P, Queinnec S, Picard L, Guissou I, Naanaa T, Duffiet P, Julian D, Archer V.

Int Orthop. 2013 Dec;37(12):2377-84. doi: 10.1007/s00264-013-2066-3. Epub 2013 Aug 24.


Implementation of a smoke-free policy in a high secure mental health inpatient facility: staff survey to describe experience and attitudes.

Hehir AM, Indig D, Prosser S, Archer VA.

BMC Public Health. 2013 Apr 8;13:315. doi: 10.1186/1471-2458-13-315.


Smoking and other drug characteristics of aboriginal and non-aboriginal prisoners in australia.

Richmond RL, Indig D, Butler TG, Wilhelm KA, Archer VA, Wodak AD.

J Addict. 2013;2013:516342. doi: 10.1155/2013/516342. Epub 2013 Mar 31.


A randomized controlled trial of a smoking cessation intervention conducted among prisoners.

Richmond R, Indig D, Butler T, Wilhelm K, Archer V, Wodak A.

Addiction. 2013 May;108(5):966-74. doi: 10.1111/add.12084. Epub 2013 Mar 11.


Evaluation of a smoke-free forensic hospital: patients' perspectives on issues and benefits.

Hehir AM, Indig D, Prosser S, Archer VA.

Drug Alcohol Rev. 2012 Jul;31(5):672-7. doi: 10.1111/j.1465-3362.2012.00456.x. Epub 2012 Apr 24.


The challenges of reducing tobacco use among prisoners.

Richmond RL, Butler TG, Indig D, Wilhelm KA, Archer VA, Wodak AD.

Drug Alcohol Rev. 2012 Jul;31(5):625-30. doi: 10.1111/j.1465-3362.2012.00435.x. Epub 2012 Mar 26. Review.


Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.


Cardiovascular risk among Aboriginal and non-Aboriginal smoking male prisoners: inequalities compared to the wider community.

Richmond RL, Wilhelm KA, Indig D, Butler TG, Archer VA, Wodak AD.

BMC Public Health. 2011 Oct 10;11:783. doi: 10.1186/1471-2458-11-783.


Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C; BO17704 Study Group.

Ann Oncol. 2010 Sep;21(9):1804-9. doi: 10.1093/annonc/mdq020. Epub 2010 Feb 11.


Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C.

J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415.


Indoor radon and lung cancer risk in connecticut and utah.

Sandler DP, Weinberg CR, Shore DL, Archer VE, Stone MB, Lyon JL, Rothney-Kozlak L, Shepherd M, Stolwijk JA.

J Toxicol Environ Health A. 2006 Apr;69(7):633-54.


Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K.

Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37.


Latency and the lung cancer epidemic among United States uranium miners.

Archer VE, Coons T, Saccomanno G, Hong DY.

Health Phys. 2004 Nov;87(5):480-9.


Supplemental Content

Loading ...
Support Center